United States - English - NLM (National Library of Medicine)

citron pharma llc - zidovudine (unii: 4b9xt59t7s) (zidovudine - unii:4b9xt59t7s) - zidovudine 300 mg - zidovudine tablets, usp, a nucleoside reverse transcriptase inhibitor, are indicated in combination with other antiretroviral agents for the treatment of hiv-1 infection. zidovudine tablets, usp are indicated for the prevention of maternal-fetal hiv-1 transmission [see dosage and administration (2.3)].  the indication is based on a dosing regimen that included 3 components: - antepartum therapy of hiv-1 infected mothers - intrapartum therapy of hiv-1 infected mothers - post-partum therapy of hiv-1 exposed neonate points to consider prior to initiating zidovudine tablets, usp in pregnant women for the prevention of maternal-fetal hiv-1 transmission include: - in most cases, zidovudine tablets, usp for prevention of maternal-fetal hiv-1 transmission should be given in combination with other antiretroviral drugs. - prevention of hiv-1 transmission in women who have received zidovudine tablets, usp for a prolonged period before pregnancy has not been evaluated. - because the fetus is most susceptible to the pote

United States - English - NLM (National Library of Medicine)

mylan pharmaceuticals inc. - zidovudine (unii: 4b9xt59t7s) (zidovudine - unii:4b9xt59t7s) - zidovudine 300 mg - zidovudine tablets usp, a nucleoside reverse transcriptase inhibitor, are indicated in combination with other antiretroviral agents for the treatment of hiv-1 infection. zidovudine tablets are indicated for the prevention of maternal-fetal hiv-1 transmission [see dosage and administration (2.3)]. the indication is based on a dosing regimen that included three components: points to consider prior to initiating zidovudine tablets in pregnant women for the prevention of maternal-fetal hiv-1 transmission include: zidovudine tablets are contraindicated in patients who have had a potentially life-threatening hypersensitivity reaction (e.g., anaphylaxis, stevens-johnson syndrome) to any of the components of the formulations. in humans, treatment with zidovudine during pregnancy reduced the rate of maternal-fetal hiv-1 transmission from 24.9% for infants born to placebo-treated mothers to 7.8% for infants born to mothers treated with zidovudine [see clinical studies (14.3)]. there were no differences in pregnancy-r

United States - English - NLM (National Library of Medicine)

cipla ltd. - zidovudine (unii: 4b9xt59t7s) (zidovudine - unii:4b9xt59t7s) - zidovudine 300 mg - zidovudine, a nucleoside reverse transcriptase inhibitor, is indicated in combination with other antiretroviral agents for the treatment of hiv-1 infection. zidovudine is indicated for the prevention of maternal-fetal hiv-1 transmission [see dosage and administration (2.3)]. the indication is based on a dosing regimen that included 3 components: - antepartum therapy of hiv-1 infected mothers - intrapartum therapy of hiv-1 infected mothers - post-partum therapy of hiv-1 exposed neonate points to consider prior to initiating zidovudine in pregnant women for the prevention of maternal-fetal hiv-1 transmission include: - in most cases, zidovudine for prevention of maternal-fetal hiv-1 transmission should be  given in combination with other antiretroviral drugs. - prevention of hiv-1 transmission in women who have received zidovudine for a prolonged period before pregnancy has not been evaluated. - because the fetus is most susceptible to the potential teratogenic effects of drugs during the first 10 weeks of ges

United States - English - NLM (National Library of Medicine)

state of florida doh central pharmacy - zidovudine (unii: 4b9xt59t7s) (zidovudine - unii:4b9xt59t7s) - zidovudine 300 mg - zidovudine, a nucleoside reverse transcriptase inhibitor, is indicated in combination with other antiretroviral agents for the treatment of hiv-1 infection. zidovudine tablets are indicated for the prevention of maternal-fetal hiv-1 transmission [see dosage and administration (2.2)]. the indication is based on a dosing regimen that included three components: - antepartum therapy of hiv-1 infected mothers - intrapartum therapy of hiv-1 infected mothers - post-partum therapy of hiv-1 exposed neonate. points to consider prior to initiating zidovudine tablets in pregnant women for the prevention of maternal-fetal hiv-1 transmission include: - in most cases, zidovudine tablets for prevention of maternal-fetal hiv-1 transmission should be given in combination with other antiretroviral drugs. - prevention of hiv-1 transmission in women who have received zidovudine tablets for a prolonged period before pregnancy has not been evaluated. - because the fetus is most susceptible to the potential teratogenic effects of d

Canada - English - Health Canada

glaxo wellcome inc. - zidovudine - tablet - 300mg - zidovudine 300mg - nucleoside and nucleotide reverse transcriptase inhibitors

United States - English - NLM (National Library of Medicine)

fresenius kabi usa, llc - aztreonam (unii: g2b4ve5gh8) (aztreonam - unii:g2b4ve5gh8) - aztreonam 1 g - to reduce the development of drug-resistant bacteria and maintain the effectiveness of aztreonam for injection, usp and other antibacterial drugs, aztreonam for injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. aztreonam for injection is indicated for the treatment of the following infections caused by susceptible gram-negative microorganisms: urinary tract infections (complicated and uncomplicated), including pyelonephritis and cystitis (initial and recurrent) caused by escherichia coli, klebsiella pneumoniae, proteus mirabilis, pseudomonas aeruginosa, enterobacter cloacae, klebsiella oxytoca *, citrobacter species*, and serratia marcescens *. lower respiratory t

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

milpharm ltd - lamivudine; zidovudine - tablet - 150mg ; 300mg

Malta - English - Medicines Authority

mylan s.a.s. 117 allee des parcs, 69800 saint priest, france - zidovudine, lamivudine - film-coated tablet - zidovudine 300 milligram(s) ; lamivudine 150 milligram(s) - antivirals for systemic use

Malta - English - Medicines Authority

mylan pharmaceuticals limited damastown industrial park mulhuddart dublin15 dublin, ireland - zidovudine, lamivudine - film-coated tablet - zidovudine 300 mg lamivudine 150 mg - antivirals for systemic use

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

aurobindo pharma ltd - zidovudine - capsule - 100mg